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Objective - HLA-B27 is associated with the inflammatory spondyloarthropathies (SpAs). Of 
significance, subtypes HLA-B*27:06 and HLA-B*27:09 are not associated with the SpAs. 
These subtypes primarily differ from the HLA-B*27:05 disease associated allele at residues 
114 and 116 of the heavy chain, part of the F pocket of the antigen-binding groove. 
Dimerisation of HLA-B27 during assembly has been implicated in disease onset. This study 
investigated the factors influencing differences in dimerisation between disease associated 
and non-associated HLA-B27 alleles.  
 
Methods – HLA-B*27:05 and mutants resembling the HLA-B*27:06 and 09 subtypes were 
expressed in the rat C58 T cell line, the human CEM T cell line and its calnexin deficient 
variant CEM.NKR. Immunoprecipitation, pulse chase, flow cytometry and immunoblotting 
were performed to study the assembly kinetics, heavy chain dimerisation and chaperone 
associations. 
 
Results - By expressing HLA-B*27:05, 06-like and 09 alleles on a restrictive rat TAP peptide 
transporter background, we demonstrate that a tyrosine expressed at p116 or together with 
an aspartic acid residue at p114 inhibited HLA-B27 dimerisation and increased the assembly 
rate. F pocket residues alter the associations with chaperones of the early MHC class I 
folding pathway. Calnexin was demonstrated to participate in endoplasmic reticulum (ER) 
stress mediated degradation of dimers, whereas the oxidoreductase ERp57 does not appear 
to influence dimerization.  
 
Conclusion - Residues within the F pocket of the peptide-binding groove differing between 
disease-associated and non-disease-associated HLA-B27 subtypes can influence the 
assembly process and heavy chain dimerisation, events which have been linked to the 
initiation of disease pathogenesis. 
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Human Leukocyte Antigen (HLA)-B27 is a major histocompatibility complex (MHC) class I 
molecule that exhibits a strong association with inflammatory arthritic conditions that are 
collectively referred to as the Spondyloarthropathies (SpAs) (1, 2). HLA-B27 exhibits an 
enhanced tendency to misfold and form aberrant dimeric structures (3, 4). HLA-B27 dimers 
were initially detected following recombinant protein purification and have subsequently been 
detected both in vivo in various cell lines (5-7) and in human patient derived cell types (8, 9). 
HLA-B27 dimer expression has also been correlated with disease incidence in the HLA-B27 
rat transgenic model for Ankylosying Spondylitis (AS) (10). HLA-B27 heavy chain dimers 
were thought to form primarily via an unpaired cysteine (C) at position (p) 67 (7). 
Subsequently, we have demonstrated that HLA-B27 dimerisation inside cells can also involve 
the structurally conserved cysteines within the α2-domain of the heavy chain at p101 and 
p164 (6, 11).  
 
Two HLA-B27 subtypes, HLA-B*27:06 and 09 exhibit no association with AS (12-14), though 
some contradictory data has previously been reported for HLA-B*27:09 (15, 16). These two 
subtypes have generated much interest due to their limited sequence differences compared 
to the canonical disease associated subtype HLA-B*27:05. HLA-B*27:09 possesses only an 
aspartic acid to histidine change at p116 (D116H), whilst the 06 subtype expresses an 
histidine to aspartic acid and an aspartic acid to tyrosine change at p114 and p116 
respectively (termed 06-F pocket in this study) when compared to HLA-B*27:05. In addition 
HLA-B*27:06 expresses an aspartic acid to serine and valine to glutamate change at p77 and 
p152 respectively as well an alanine to glycine change at p211 within the α3 domain in 
comparison to HLA-B*27:05. The residues expressed by HLA-B*27:06 at p77 and p152 are 
shared with HLA-B*27:04, however 04 shares the same F pocket residues with HLA-B*27:05. 
Structurally, p114-116 constitute part of the F pocket of the peptide binding groove which 
binds and determines the carboxy (C) terminal motif of MHC class I associated peptides (17), 
but it can also influence other anchor positions (18). The 114-116 region also determines the 
ability of MHC class I molecules to use tapasin in optimising the peptide cargo and hence 
associate with the peptide-loading complex (PLC) during assembly in the ER (19). Thus the 
lack of association of the 06 and 09 subtypes with the SpA could support a role for either 
antigen presentation or protein folding participating in disease pathogenesis. 
HLA-B27 dimerisation within the ER occurs early during MHC class I biosynthesis (5) and the 
maturation rate affects interactions between MHC class I heavy chains and pre-PLC 
associated chaperones (6). We have previously demonstrated that HLA-B*27:05, 06 and 09 
subtypes differ in their cysteine accessibility to thiol-modifying drugs (6, 20) and recently 
characterised the ER stress associated degradation (ERAD) pathway of misfolded HLA-B27, 
involving the ERAD components EDEM1 and the E3 ubiquitin ligase HRD1 (8). We reasoned 
that if misfolding, particularly HC-dimerisation, is involved in disease pathogenesis, the HLA-
B*27:06 and 09 subtypes should exhibit differences in their biochemical characteristics in 
comparison to HLA-B*27:05. We set out to test if 06 and 09 F pocket differences determine 
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which, if any, of the ER resident chaperones are involved in the dimerisation process and how 
these specific residues affect HLA-B27 folding. We demonstrate a role for calnexin in ER 
stress induced ERAD of HLA-B27 dimers, which is consistent with our proposed function for 
EDEM1 in dimer degradation (8). We also show a correlation between maturation rates and 
dimer formation, especially with F pocket residues expressed by the HLA-B*27:06 allele. 
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Materials and Methods 
 
Cell lines and antibodies. The rat T cell line C58 (21) and the human T cell leukemia lines 
CEM and CEM.NKR were maintained in RPMI1640, supplemented with 10% FBS 
(Globepharm), penicillin, streptomycin and L-glutamine (R10 media) and maintained at 5% 
CO2 and 37ºC. C58.B*27:05, H114D, HLA-B*27:09 (D116H), D116Y and 06 F Pocket 
(H114DD116Y), CEM.B*27:05, 06 F Pocket, HLA-A*02:01 and CEM.NKR.B*27:05, 06 F 
pocket and HLA-A*02:01  transfectants were generated by electroporation at 900 µF, 180 V 
and maintained in R10 media plus G418 (1 mg/ml). All constructs also included a V5 C-
terminal tag. HEK 293 cells were maintained in R10 medium and transfected with shRNA 
targeted to ERp57 in the pSilencer 2.1 vector using Lipofectamine 2000 (both Life 
Technologies). Anti-V5 antibody (pK) was obtained from Serotec. Monoclonal antibody HC10 
primarily recognises unfolded HLA-B and –C molecules. Anti-BiP and -CNX antibodies were 
obtained from Stressgen and anti-ERp57 from Abcam. Anti-BiP, -HERP and GAPDH 
antibodies were obtained from Santa Cruz Biotechnology. Goat anti-mouse HRP conjugated 
secondary antibody was obtained from DAKO and anti-rabbit monoclonal HRP from Sigma. 
 
Site Directed Mutagenesis. For mutagenesis, a V5 C-terminally tagged cDNA encoding the 
HLA-B*27:05 allele, cloned into the mammalian expression vector pCR3.1 (Invitrogen) was 
mutated using PCR based site directed mutagenesis (Stratagene Quickchange) protocol as 
previously described (22).  
 
Pulse Chase. Approx. 5 x 10
6
 cells were preincubated in methionine free RPMI (Gibco), for 
20 mins, labelled with 7.2 Mbq 
35
S-Trans label (MP Biologicals) for 10 mins, washed and 
resuspended in R10 media. Aliquots were removed at specified times, lysed in 1% NP40 lysis 
buffer (150 mM NaCl, 10 mM Tris pH 7.4, 1 % NP40), supplemented with 1 mM PMSF, 1x 
complete protease inhibitors (Roche) and 10 mM NEM (Sigma). Samples were precleared for 
30 mins with Protein A sepharose  (Sigma) and immunoprecipitated with pK conjugated to 20 
µl protein A sepharose for 1hr at 4ºC. Samples were resolved on 8% SDS-PAGE gels and 
processed for autoradiography. 
 
Immunoprecipitation. Approx. 5 x 10
7
 of each cell line were incubated with 20 mM 
NEM/PBS pH 6.8 on ice for 20 mins, followed by lysis in 1% NP40 lysis buffer. Lysates were 
precleared for 1hr at 4ºC, followed by immunoprecipitation with pK antibody (for MHC class I 
heavy chain immunoprecipitations) for 2 hrs at 4ºC. Immunoprecipitates were washed 5 x 0.5 
mls with lysis buffer.   
 
Immunoblotting. Samples were resolved on 8% SDS-PAGE, transferred onto nitrocellulose 
(BA85, Schleicher and Scheull), blocked for 1 hr with 5% skimmed milk powder in PBS/0.1% 
Tween, followed by overnight incubation with respective antibodies, followed by second stage 
HRP coupled antibodies. Images were revealed by chemiluminescence using Supersignal 
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Femto (Pierce). Images were developed on a BIORAD Fluoro-S Multimagere Max imager 
using Quantity One 1D analysis software. 
 
Flow Cytometry. Approx 5 x 10
5
 cells were incubated with ME1 or HC10 supernatant for 30 
mins at 4°C, washed in PBS/1%FCS and incubated with FITC coupled anti-mouse antibodies 
for 30 mins, washed and fixed in 1% paraformaldehyde. Cells were analysed on a 
FACScalibur (Becton Dickinson).  
 
qPCR quantitation. cDNA was generated using oligo dT primers and the Superscript
™
 III 
First Strand Synthesis kit (Invitrogen) according to manufacturer’s conditions. Probes and 
primers specific for the spliced and unspliced mRNA transcripts for the human XBP-1 gene 
used sequence NM_005080 and for HLA-B*27:05 used the IMGT/HLA database (accession 
number HLA-00225, specific for HLA-B*27:05).  Sequences were as follows; XBP-1 
unspliced   CACTCAGACTACGTGCACCTCTG (forward), XBP-1 
spliced  CTGAGTCCGCAGCAGGTG (forward),  XBP-1 CAGAATCCATGGGGAGATGTT 
(reverse), XBP-1 CAGGCCCAGTTGTCACCCCTCCA (probe). For HLA-
B*27:05,   GACACAGATCTGCAAGGCCA (forward),  TTGTAGTAGCGGAGCAGGGTC 
(reverse), CGCAGGTCCTCTCGGTCAGTCTGTG (probe). Probes and primers for the human 
ß-actin gene were obtained from Applied Biosystems (Part number 4333762T). 50 ng cDNA 
was tested in duplicate. Real time PCR was performed using conditions; 95ºC for 10 mins, 40 
cycles of 95ºC for 15 secs and 64ºC for 1 min. 
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Results 
 
Characterisation of cells expressing F pocket mutated HLA-B27 molecules. The 
locations of positions 114 and 116 in the F pocket, where the key polymorphisms between the 
HLA-B*27:05, 06 and 09 subtypes reside are shown in Figure 1A. We generated sets of C-
terminal V5 tag HLA-B27 molecules with single residue substitutions found in different 
subtypes i.e. B27.H114D, B27.D116Y, B27.D116H (equivalent to the 09 subtype) or in 
combination i.e. B27.H114DD116Y (06-like, referred to hereafter as 06 F pocket) and 
expressed these in the rat thymoma C58 cell line. The C58 line has a RT1
u
 MHC background 
which is also shared with the PVG rat strain, which develops AS like disease in the presence 
of HLA-B27 (23, 24).  The RT1
U
 TAP peptide transporter confers a more restrictive peptide 
transport profile than human TAP and is biased towards peptides with hydrophobic C-termini 
only (25). We reasoned that this more restricted TAP background might reveal factors 
influencing HLA-B27 assembly. 
 
Analysis of cell surface expression of HLA-B*27:05 and the p114-116 subtype polymorphisms 
using the monoclonal antibodies ME1 (detecting folded HLA-B27) and HC10 (detecting 
partially unfolded HLA-B and –C molecules), indicated that residues expressed at p114-116 
can alter cell surface expression in the RT1
u
 MHC background. The H114D substitution led to 
a reduction in cell surface expression (Figure 1B). HC10 expression overall mirrored those of 
ME1, Quantitative (q) PCR (data not shown) and protein expression analysis demonstrated, 
with the exception of HLA-B*27:09, all mutants were expressed within three fold of the HLA-
B*27:05 subtype. In addition, this data indicates the reduced cell surface expression observed 
for H114D was not the result of a deficit of HLA-B27 heavy chain expression  (Figure 1C).  
 
Residues at p114-116 influence the association with chaperones. It has been previously 
demonstrated that HLA-B*27:05 dimerisation occurs soon after translation (5) (and our 
unpublished observations) and F pocket residues can affect MHC class I assembly (26), 
therefore it is possible that ER resident chaperones associating with newly synthesized 
proteins may influence how these dimers are generated. The HLA-B27 heavy chain was 
immunoprecipitated, followed by immunoblotting for co-precipitating ER resident chaperones 
to determine which, if any of these residues influenced ER resident chaperone associations. 
Cells expressing HLA-B*27:05 and p114-116 substitutions were incubated with NEM to 
preserve transient disulfide bond interactions, lysed and immunoprecipitated through the anti-
V5 epitope, resolved by non-reducing SDS-PAGE and immunoblotted for ERp57, calnexin 
(CNX), BiP, calreticulin (CRT) (data not shown), PDI (data not shown) and TPN (data not 
shown). HLA-B*27:05, H114D and HLA-B*27:09 formed conjugates with ERp57 and 
associated with CNX and BiP (Figure 2). The ERp57 immunoblot analysis also revealed 
several high molecular mass ERp57-MHC class I heavy chain conjugates (Figure 2, arrows 
b-f) as well as ERp57 monomers (Figure 2, arrow a). The ERp57-B27 conjugates were 
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different in size to HLA-B27 heavy chain dimers (data not shown). In contrast, there was 
lower association of these chaperones with the D116Y and 06 F pocket heavy chains. No 
association could be detected under these experimental conditions between HLA-B27 and 
PDI, CRT and TPN (data not shown), likely due to the use of NP40, which does not preserve 
most PLC interactions (27). Thus, F pocket differences amongst the HLA-B27 subtypes 05, 
06 and 09 can influence associations with the chaperones CNX, BiP and the oxidoreductase 
ERp57 which can associate with newly synthesized proteins (28). 
 
Calnexin and F pocket residues regulate HLA-B27 heavy chain dimer formation. CNX 
can control both the degradation and folding of substrate proteins including MHC class I 
molecules (29-31). We have previously shown that EDEM1 is involved in the ERAD of HLA-
B27 dimers (8) with CNX integral to its function (32, 33). We therefore hypothesized that CNX 
may play a pivotal role in HLA-B27 dimerisation. To examine the role of CNX, we utilised the 
CNX deficient human cell line CEM.NKR. We transfected both the parental CNX expressing 
cell line CEM and CEM.NKR with HLA-B*27:05, 06 F Pocket, and as a control the non-
disease associated MHC class I molecule HLA-A*02:01. The respective cell lines were NEM 
treated, lysed and proteins resolved by SDS-PAGE. Immunoblotting for MHC class I heavy 
chain revealed that HLA-B*27:05 produced dimer populations in CEM cells, whilst the control 
HLA-A*02:01 did not (Figure 3A, left panel). In NKR cells, HLA-B*27:05 displayed enhanced 
dimer formation (Figure 3A, middle panel). We could not detect dimers in either CEM or 
CEM.NKR cells expressing HLA-B*27:06 F pocket heavy chain (Figure 3B, right panel). 
Protein expression and qPCR analysis revealed that both CEM.B27 and NKR.B27 cell lines 
expressed similar levels of transfected HLA molecules (data not shown). The failure of HLA-
A*02:01 to form dimer populations in normal or CNX deficient cell lines, indicates that the 
absence of CNX does not in itself cause the formation of HLA aggregates. These 
observations suggest CNX inhibits and/or reduces the formation of HLA-B27 dimers. 
 
HLA-B27 can assemble in the absence of calnexin. The above data suggests that CNX 
regulates heavy chain dimers. We next studied the impact of CNX deficiency upon the 
expression and kinetics of HLA-B27 assembly. Cell surface expression of ME1 and HC10 
reactive forms of HLA-B27 was determined. HLA-B*27:05 was similarly expressed by both 
CEM.B*27:05 and NKR.B*27:05 lines and as detected by ME1, whereas the HC10 staining 
was approximately two fold less in the absence of CNX (Figure 3B & C). Thus there are 
more partially folded or misfolded molecules at the cell surface in the presence of CNX. We 
next analysed the assembly kinetics by pulse chase analysis. HLA-B*27:05 displayed little 
acquisition of endo H resistance over 3 hrs chase, both in wild type or CNX deficient cells 
(Figure 3D). Over a longer time course endo H resistant material appeared at 3.5 hrs both in 
the wild type and calnexin deficient cells, with a slight increase in endo H resistant material 
evident in the presence of calnexin, quantified as 38% and 46% endo H resistant at 3.5 and 5 
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hours respectively in CEM cells, compared to 17% and 28% in NKR cells (Figure 3E). Thus 
the presence of CNX promoted faster assembly kinetics, but paradoxically this may result in 
less stable molecules which dissociate more readily at the cell surface.  
 
HLA-B*27:05 heavy chain dimer detection is not dependent on ERp57 but ERAD is 
modulated by calnexin. CNX binds and recruits the oxidoreductase ERp57 (34) thus the 
absence of calnexin could potentially disrupt HLA-B*27:05 associations with ERp57, which 
may impact on dimerization. Therefore we immunoprecipitated MHC class I heavy chains 
from both CEM.B*27:05 and NKR.B*27:05 lines and immunoblotted for ERp57 associated 
with HLA-B27 (Figure 4A). ERp57 was associated with HLA-B*27:05 in both wild type and 
calnexin deficient cells. To determine if heavy chain dimerization was influenced by ERp57, 
we stably shRNA inhibited ERp57 in 293T cells (Figure 4B) followed by transient transfection 
with HLA-B*27:05. In the absence of ERp57, HLA-B27 retained the ability to dimerise (Figure 
4C), however, minor alterations in the pattern of dimers were observed in ERp57 deficient 
cells, suggesting ERp57 may influence the composition of the dimerised pool. 
 
Calnexin participates in degradation of misfolding polypeptide substrates in conjunction with 
the ER stress associated EDEM1 protein (33). We therefore examined if enhanced dimer 
levels were a result of reduced degradation in the absence of calnexin. CEM.B*27:05 and 
NKR.B*27:05 cells were therefore treated with tunicamycin, which induces ER stress induced 
ERAD responses (8). In the presence of calnexin, HLA-B27 dimers were absent following ER 
stress induction, however in the absence of calnexin, heavy chain dimers were retained 
(Figure 4D). To discount the possibility that calnexin deficient cells were unable to induce an 
ER stress response, we treated cells with tunicamycin or DTT and monitored the UPR 
activation markers BiP, the XBP-1 spliced (XBP-1s) transcription factor and the 
homocysteine-inducible ER stress protein (HERP) which is activated by XBP-1s. 
Pharmacological induction of ER stress led to enhanced BiP (2.9 and 5.4 fold increase in 
CEM and NKR respectively) and HERP (1.2 and 1.9 fold increase in CEM and NKR 
respectively) expression as detected by immunoblotting and enhanced XBP-1s transcript 
levels as determined by qPCR. Therefore in the absence of calnexin, the UPR can be 
induced (Figure 4E & F).  
 
Residues at p114-116 alter dimerisation and maturation kinetics of HLA-B27. The 
above analysis demonstrated that F pocket residues can influence chaperone associations. 
We have previously hypothesized that the rate of maturation can correlate with dimer 
formation (6). We therefore examined how the F pocket residues influenced HLA-B27 
dimerisation in rat C58 cells. D116Y had a reduced tendency to dimerise (Figure 5A, top 
panel), as did the 06 F pocket mutant (Figure 5A, bottom panel). After overnight incubation 
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at 26
o
C to slow the assembly kinetics, both the D116Y and 06 F pocket mutants displayed 
an ability to dimerise (Figure 5A, bottom panel), indicating there was no overall structural 
constraints preventing dimerisation.  
 
Previously, we demonstrated that the ability of HLA-B27 to dimerise correlated with assembly 
kinetics (6), therefore we determined the effect that each of the F pocket residues had on the 
assembly kinetics of HLA-B27 (Figure 5B). HLA-B*27:05, B27.H114D, HLA-B*27:09, D116Y 
and 06 F pocket expressing cells were analysed by pulse chase. In this experiment we used 
an anti-V5 antibody directed at the C-terminus for the immunoprecipitation and were therefore 
able to detect all HLA-B27 molecules in an unbiased manner. Only a small proportion of the 
total HLA-B*27:05 and H114D molecules acquired endo H resistance (r) after 90 mins of 
chase, 3% and 0.5% respectively (Figure 5B), indicating that they remain within the ER for 
prolonged periods. However, residue changes at p116 dramatically changed maturation 
rates. HLA-B*27:09 (10% endo H resistant at 90 mins) has a markedly faster maturation rate 
than HLA-B*27:05, whilst the D116Y substitution was sufficient to further dramatically alter 
the maturation kinetics (29% at 90 mins). The 06 F pocket expressing HLA-B27 molecule 
exhibited an even faster maturation rate than the D116Y mutant (50% at 90 mins). Therefore, 
residues at p114-116 in the F pocket can have a dramatic impact on the maturation rate of 
HLA-B27. 
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Discussion. 
The role that HLA-B27 plays in the pathogenesis of inflammatory arthritis remains elusive. 
Our data indicate that the residues at p114-116 dramatically affect the folding and dimer 
formation characteristics of HLA-B27 (summarised in cartoon form in Figure 6).  Much of the 
focus regarding dimerisation has centered around C67, however our earlier observations and 
those of others suggested that C67 is not the sole cysteine responsible for dimerisation and 
that C164 may also participate in this process (6, 11). Previously, we demonstrated that 
p114-116 of HLA-B27 was also important in determining whether cysteine residues were 
exposed and reactive (20) (Figure 6C-D). The reduced tendency by D116Y and 06 F pocket 
mutant heavy chains to dimerise, may be related to the temporal exposure of reactive 
cysteines to the oxidizing environment of the ER (Figure 6B). Thus, together with the 
residues expressed at p114-116, the unpaired and structural cysteines proposed to be 
involved in dimerization may result in the ER resident population of heavy chain dimers being 
a complex mix of disulfide species involving multiple cysteine residues.   
 
It has also been proposed that HLA-B27 dimers at the cell surface and within the cell may 
play a distinct role in disease pathogenesis (3, 35). ER resident dimers have been 
hypothesised to induce ER stress responses, possibly leading to proinflammatory cytokine 
production (35, 36). Cell surface dimers on the other hand lead to aberrant recognition by 
immune receptors (37, 38). In preliminary experiments with the HD6 antibody reagent that 
identifies cell surface HLA-B27 dimeric structures (39) we found no significant impact caused 
by the position 114 and 116 variants studied here, further supporting the idea that the cell 
surface HLA-B27 dimers are a distinct pool from the ER-resident forms (data not shown).  
 
These current observations indicate that residues within the peptide-binding groove, 
representing polymorphisms found in HLA-B27 subtypes not associated with disease, play a 
critical role in determining the maturation rate of the molecule. Earlier work using 
conformationally specific antibodies ME1 and W6/32 (40, 41) corroborate our unbiased 
approach of monitoring HLA-B27 molecules expressing F pocket changes. These studies 
demonstrated that polymorphisms at p116 enhanced the acquisition of W6/32 and ME1 
epitopes as well as affecting the ratio of folded vs HC10 reactive populations. Therefore, we 
suggest that the maturation rate of the HLA-B27 molecule influences whether cysteine 
residues are exposed to the oxidizing environment of the ER long enough to participate in 
aberrant disulfide bonding (Figure 6B-D).  
 
The aspartic acid residue at p114 is expressed together with a tyrosine at p116 by HLA-
B*27:06. However, the H114D mutation alone has a dramatic effect on cell surface 
expression levels of HLA-B27 compared to HLA-B*27:05 (Figure 1B), a finding consistent 
with previous observations (40). Interestingly, expression is restored to wild type levels at 
reduced temperatures ((40) and our unpublished observations), which indicates that there are 
Page 11 of 26
John Wiley & Sons
Arthritis & Rheumatology
This article is protected by copyright. All rights reserved.
 12
probably no gross primary structural alterations. Recently, biophysical and biochemical 
observations suggest that the HLA-B*27:05 and 04 peptide binding grooves exhibit greater 
degrees of flexibility and disorder when compared to HLA-B*27:06 and 09 (42, 43). It is 
possible that the cell surface expression levels that we observe in our peptide restricted 
environment, could be a reflection of the level of disorder within the HLA-B27 peptide-binding 
groove. The expression of tyrosine or histidine at p116 could reduce disorder (43), which may 
enhance peptide-binding stability, leading to improved folding dynamics and subsequently 
enhanced cell surface expression. However, the expression of aspartic acid at p114 in 
combination with an aspartic acid at p116 could increase the molecular disorder of the 
binding groove and disrupt the stability of peptide-MHC complexes. 
 
Y116 appears to rescue or be dominant in its effect on HLA-B27 folding, which highlights that 
certain combinations of residues can influence MHC class I assembly (40, 44). Our 
observations highlight how the F pocket residues of HLA-B*27:06 affect the early stages of 
folding and dimerization. However, it would be of interest to determine any further effects of 
the HLA-B*27:06 serine and glutamate residues at p77 and p152 respectively. We can 
postulate that evolutionary pressure on MHC polymorphisms can select for combinations of 
residues, not only to enable the effective presentation of peptide, but also to allow for efficient 
folding and expression of MHC class I molecules. The above findings indicate that predicting 
the actual outcome of multiple mutations within the antigen binding groove on MHC class I 
molecules is difficult.  
 
Intriguingly, the tyrosine at p116 is shared with HLA-B*27:07 which has been described as a 
subtype both associated and non-associated with AS. However, many studies suggest that 
HLA-B*27:07 exhibits a weaker association with AS (45, 46).  Studies have demonstrated that 
HLA-B*27:07 and 06 can oligomerise to different extents (47). It remains undetermined how 
an asparagine at p114 in the absence of tyrosine and how the HLA-B*27:07 F pocket can 
affect the biochemical parameters we have described here. Our findings are consistent with 
previous observations that Y116 does enhance the maturation rate (44), but whether this is 
an important parameter in AS development remains undetermined. Our analysis does reveal 
differences in maturation rates and levels of dimerised HLA-B27 molecules. These 
observations could reflect differences between the rat C58 line with a restricted HLA-B27 
binding peptide repertoire compared to human B and T lymphoblastoid lines such as CIR and 
174.221.  
 
HLA-B27 polymorphisms expressed at p114-116 can influence chaperone associations. 
These residues were thought to determine the requirement for tapasin within the PLC (19). In 
relation to HLA-B27, it has been described that polymorphisms expressed within the peptide 
binding groove by HLA-B27 subtypes influence thermostability (41, 48), F pocket flexibility 
(43) and requirement for tapasin (40). Here, we extend these studies to chaperones 
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associated with early folding events (Figure 6). It is possible that MHC class I heavy chain 
levels could influence chaperone associations. The higher expression levels of HLA-B*27:09 
(Figure 1) could indeed account for BiP, calnexin and ERp57 co-precipitating with this 
molecule. D116Y and the 06 F pocket mutants, though expressed approximately 3 fold higher 
than HLA-B*27:05, only exhibit minimal levels if any at all of the co-precipitating chaperones 
(Figure 2). Previously, we have demonstrated that chaperone associations may depend on 
the MHC class I allele and rate of maturation. Incubation at reduced temperature can 
enhance chaperone associations (6). By reducing the temperature to 26°C, both D116Y and 
the 06 F pocket heavy chains can dimerise (Figure 5) and under these conditions, calnexin, 
BiP and ERp57 can be detected (our unpublished observations). These observations suggest 
that the folding and misfolding characteristics of MHC class I heavy chains are a predominant 
factor influencing chaperone association. Therefore, our data demonstrate that residues at 
p114 and 116 can influence associations with the oxidoreductase ERp57 and the 
chaperones, calnexin and BiP (Figure 2), which are involved in both early folding events of 
secretory proteins and their degradation (28, 49).   
 
Our analysis of the role of ERp57 in HLA-B27 dimer formation in NKR.B27 cells indicates that 
this oxidoreductase does not require calnexin to associate directly with MHC class I heavy 
chains. We observed that ERp57 was found to form disulfide bonded conjugates with HLA-
B27 heavy chains predisposed to forming dimeric conformations. However, ERp57 inhibition 
revealed that dimers could still be detected in the absence of ERp57. It is possible that 
dimerisation is a spontaneous event mediated by the oxidising conditions of the ER. 
However, HC-dimerisation could also be mediated by other oxidoreductases such as PDI. 
Dual inhibition of ERp57 and PDI in HLA-B27 expressing cells would address this question in 
the future. 
 
Our data also supports a key role for calnexin in modulating dimer levels (Figure 6A). In the 
absence of calnexin, dimer levels are enhanced (Figure 3). Our analysis also reveals that 
calnexin can mediate degradation of dimers following the induction of ER stress (Figure 4D). 
This analysis is consistent with our previous observations demonstrating a role for EDEM1 in 
the degradation of HLA-B27 dimers (8). EDEM1 appears to require calnexin for efficient 
degradation of misfolding proteins (33) and EDEM1 is also a target for the ER stress inducible 
XBP-1s transcription factor (50). Therefore our observations are consistent with a role for 
calnexin and EDEM1 mediating dimer levels via an ER stress degradation pathway (Figure 
6A). 
 
Whilst the rat C58 cell line used in this study is unlikely to exactly represent the normal 
situation in human cells, due to its restricted TAP peptide transporter phenotype, it has 
allowed us to reveal key constraints imposed upon HLA-B27 assembly due to the residues at 
p114-116. The 06 and 09 subtypes share overlapping peptide repertoires with HLA-B*27:05 
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(51, 52). Situations where peptide supply might become a more limiting factor could arise in 
human cells such as those expressing some of the ERAP1 polymorphisms associated with 
AS (53). It has been suggested that ERAP1 polymorphisms do not affect ER stress in AS 
patients as determined by the expression of the early and late markers GRP78 and CHOP 
respectively (54). However, our previous observations suggest that there is an ER stress 
‘footprint’ in AS derived patient samples, as determined by HRD1 expression (8). Thus, the 
detection of ER stress could be dependent on time and disease state, as well as the marker 
and cell type being analysed. Alternatively, if normal cellular homeostasis is disrupted, 
perhaps during viral or bacterial infections, or even just immune cell activation (55), this may 
also impose restrictions or alterations on peptide supply which then influences MHC class I 
peptide loading and maturation. Under these circumstances, heavy chain dimer formation 
could be enhanced and trigger an ERAD response to help clear the misfolded pool of heavy 
chains.  
 
Our study demonstrates one of the first clear mechanistic links between subtype 
polymorphisms within the F pocket of the peptide-binding groove, disease incidence and the 
biochemical properties of these HLA-B27 molecules. Our observations highlight that F pocket 
residues can affect dimerization, chaperone association and alter the maturation rates of 
HLA-B27 subtypes. The pattern of dimerization and chaperone association correlates with 
HLA-B*27:06 and its non-association with AS, suggesting that these parameters may explain 
why HLA-B27:06 does not lead to an inflammatory situation. In addition, we have shown that 
ER stress induction can lead to calnexin-dependent dimer degradation and that exploiting the 
UPR induced ERAD pathway could well be a potential novel therapeutic approach.  
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Figure Legends 
Figure 1. Illustration of p114 and p116 residues within the HLA-B27 antigen binding groove 
and expression of the p114-116 F pocket HLA-B27 molecules in the rat thymoma C58 cell 
line. (A) iCn3D generated images of the HLA-B*27:05 antigen binding groove, using structure 
1HSA.  Position 114 is indicated in blue, position 116 is indicated in green. (B) HLA-B*27:05, 
H114D, HLA-B*27:09, D116Y and 06 F pocket molecule expression at the cell surface of C58 
rat thymoma cells. The aforementioned cell lines and the untransfected (UT) C58 cell line 
were analysed by flow cytometry with antibodies ME1 and HC10. (C) Protein quantitation of F 
pocket mutants relative to HLA-B*27:05. C58 cell lines expressing HLA-B*27:05, the HLA-
B27 F pocket mutants and untransfected C58 cell line were lysed and equivalent 
concentration of protein resolved by non-reducing SDS-PAGE. Lysates were immunoblotted 
for MHC class I heavy chain and expression. 
 
Figure 2. Residues 114-116 of HLA-B27 alter ER chaperone associations.  Untransfected 
C58 cells and those expressing HLA-B*27:05 and subtype polymorphisms H114D, HLA-
B*27:09, D116Y, and the 06 F pocket were immunoprecipitated through the V5 tag and 
immunoblotted for ERp57, calnexin and BiP. Immunoblotting detected ERp57 disulfide 
conjugates with HLA-B*27:05, H114D and D116H as well as ERp57 monomer. 
Immunoblotting detected calnexin and BiP co-precipitating with HLA-B*27:05, H114D and 
HLA-B*27:09. Arrow a; monomeric ERp57, arrow b-f; HLA-B27-ERp57 disulfide bonded 
conjugates. Reduced lysates from the above cell lines were resolved by SDS-PAGE and 
immunoblotted with ERp57, calnexin and BiP illustrating equal loading. Reduced lysates were 
also probed for HLA-B27 heavy chain using the V5 tag and immunoblot analysis indicates 
approximately equal levels of MHC class I heavy chain except for HLA-B*27:09. One of four 
independent experiments is shown. 
 
Figure 3. Calnexin and 06 F pocket residues modulate levels of HLA-B27 heavy chain 
dimers, and the absence of calnexin does not significantly perturb folding kinetics of HLA-B27 
(A) HLA-B*27:05, HLA-A*02:01 and 06 F pocket were expressed in CEM and CEM.NKR 
cells. Immunoblotting for MHC class I heavy chain revealed enhanced levels of B27 dimers 
(arrows 1, 2 and 3) in NKR.HLA-B27 cells compared to CEM.B27. HLA-A*02:01 and 06 F 
pocket did not form dimers. (B) CEM.B27 and (C) NKR.B27 cells were analysed by flow 
cytometry. ME1 and HC10 reactive molecules were detected. Mean fluorescence intensities 
(MFI) figures for CEM.B27 were 2
o
:75, HC10:283 and ME1:2192. MFI figures for NKR.B27 
were 2
o
:85, HC10:174 and ME1:1851. (D and E) CEM.B27 and NKR.B27 cell lines were 
metabolically labeled for 15 mins and chased for the indicated times. Lysates were 
immunoprecipitated with the anti-V5 tag antibody, incubated with endo H and resolved by 
reducing SDS-PAGE  (one of three experiments shown). 
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Figure 4. ERp57 does not influence heavy chain dimer formation, whilst calnexin modulates 
dimer degradation via ER stress induced ERAD. (A) CEM, CEM.B*27:05, NKR and 
NKR.B*27:05 cells were immunoprecipitated for HLA-B27 with the V5 tag antibody and 
immunoblotted for ERp57. HLA-B27-ERp57 conjugates were detected in the CEM.B27 and 
NKR.B27 cell lines. (B) Stable ERp57 shRNA knockdown 293T cell lysates were 
immunoblotted for ERp57, PDI, ERp72, calreticulin (CRT) and CNX. (C) 293T wt and ERp57 
knockdowns were transiently transfected with HLA-B*27:05. Lysates were probed for MHC 
class I heavy chain using the HC10 antibody. (D) Degradation of HC-dimers via UPR induced 
ERAD in the presence but not in the absence of calnexin. CEM.B27 and NKR.B27 cells were 
treated with tunicamycin (TUN), and lysates immunoblotted for HLA-B27 using the V5 
antibody. Mock (M) treated cells were incubated with DMSO alone, untreated cells (0) (E) 
Induction of the UPR in the presence and absence of calnexin. CEM and NKR cells were 
incubated with 5 mM DTT, RNA extracted and qRT-PCR of the XBP-1 spliced product was 
determined. (F) CEM and NKR cells were treated with TUN and lysates were immunoblotted 
for BiP, HERP and GAPDH. 
 
Figure 5. F pocket p114-116 residues alter the ability of HLA-B27 to mature and dimerise. (A) 
Lysates from C58 cells expressing HLA-B*27:05, HLA-B*27:09, D116Y, H114D and HLA-
A*02:01 were resolved by non-reducing SDS-PAGE and immunoblotted for the V5 tag. The 
D116Y substitution exhibits a reduced tendency to dimerise (top panel). C58 cells expressing 
D116Y and 06 F pocket were incubated overnight at 37°C or 26°C. Lysates were then 
resolved by non-reducing SDS-PAGE and immunoblotted for the V5 tag. D116Y and 06 F 
pocket exhibit a reduced tendency to dimerise at 37°C, whilst both can dimerise following 
incubation at reduced temperature (bottom panel). (B) C58 cells with p114-116 
polymorphisms were analysed by flow cytometry with antibodies ME1, HC10 and HD6. 
Shaded histograms represent staining of untreated cells and unshaded histograms represent 
staining following acid treatment. (C) Pulse-chase analysis of HLA-B*27:05 and subtype 
polymorphisms H114D, HLA-B*27:09, D116Y and 06 F pocket (r - endo H resistant, s – endo 
H sensitive). Cell lines were metabolically labeled, chased for 0, 45 and 90 mins, 
immunoprecipitated with the anti-V5 antibody and resolved by reducing SDS-PAGE. HLA-
B*27:09, D116Y and 06 F pocket exhibit more rapid acquisition of endo H resistance (one of 
three experiments shown).  
 
Figure 6. Schematic showing the folding pathways of HLA-B27 and outcomes of ER resident 
HC-dimerisation. (A) Newly synthesized HLA-B*27:05 heavy chains translocated via the 
sec61 complex, strongly associate with calnexin (CNX)-ERp57 as well as the Immunoglobulin 
Binding Protein (BiP) (6, 10, 28). The relationship between heavy chains associated with BiP 
and CNX-ERp57 remains undefined (denoted by ‘?’). Following the non-covalent association 
with the light chain beta-2-microglobulin (β2m) CNX is displaced. HLA-B27 can acquire an 
optimal peptide cargo through the association with the peptide loading complex (PLC), whose 
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predominant constituents are the Transporter Associated with antigen Presentation (TAP), 
tapasin (TPN), calreticulin (CRT) and ERp57 (19, 28). HLA-B27 can transit to the cell surface 
independently of the PLC. HLA-B*27:05 can also form HC-dimers, which potentially can 
activate the Unfolded Protein Response (UPR) (11). The UPR induced transcription factor 
XBP-1 can target genes with a UPRE promoter sequence (50). EDEM1 and HRD1 can be 
activated by XBP-1 and together with SEL1 form an ER stress induced protein degradation 
complex (8). Through the action of CNX, HC-dimers can be targeted for destruction via the 
ER stress induced degradation complex. (B) 06 F pocket and D116Y residues result in 
transient associations with the chaperones CNX-ERp57 and BiP. Both exhibit a fast 
maturation rate (30-45 mins) of folded HLA class I molecules (40), resulting in little if any 
formation of HC-dimers. (C) HLA-B*27:09 exhibits a slower maturation rate (90 mins), which 
can result in the formation of both folded and dimeric conformers.  (D) HLA-B*27:05 and 
H114D exhibit exposed and reactive cysteines (depicted by) to a greater extent than HLA-
B*27:09 (depicted in C by ) (20). Both these molecules have an enhanced tendency to 
misfold and form HC-dimers, whilst exhibiting prolonged associations with CNX-ERp57 and 
BiP. HLA-B*27:05 molecules transit through the ER at a slow rate (3.5 hrs). For B-D, times in 
mins or hours are maturation rates of HLA-B27 heavy chains as determined by acquisition of 
endo H resistance. 
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